Document is current

Article History

Received: 4 September 2024

Accepted: 10 December 2024

First Online: 1 February 2025

Acknowledgements

: The authors are grateful to all participants in the DD2 study, and to the healthcare personnel who recruited the participants at the general practices and outpatient clinics. The authors sincerely thank the DD2 management and DD2 data managers. An abstract version of this study was presented at the ADA 2024 annual meeting in Orlando, Florida (21–24 June 2024) and at the EASD 2024 annual meeting in Madrid (10–13 September 2024).

: Danish data protection legislation does not allow sharing of the individual-level personal data used for this study. However, a data dictionary for variables used in the study and analysis code is in preparation and will be shared and made publicly available on the DD2 website, when available. Requests to access the Danish health registries used in this study may be sent from researchers at authorised research institutions to the Danish Health Data Authority by email (forskerservice@sundhedsdata.dk). Requests to use the primary DD2 data may be made by email using the link at .

: Open access funding provided by Lund University. The DD2 study was supported by the Danish Agency for Science (grant numbers 09-067009 and 09-075724), the Danish Health and Medicines Authority, the Danish Diabetes Association, the Region of Southern Denmark and the Novo Nordisk Foundation (grant numbers NNF17SA0030962-2, NNF2000063292, NNF17SA0030364, NNF18CC0034900 and NNF23SA0084103). The project partners are listed on the website. The work was partly funded by the Swedish Research Council (EXODIAB, 2009-1039; 2018-02837). The funders of the study were not involved in the design of the study, the collection, analysis and interpretation of data, or writing the report. They did not impose any restrictions regarding publication of the report. The Department of Clinical Epidemiology, Aarhus University, receives funding for other studies in the form of institutional research grants to (and administered by) Aarhus University.

: CB owns stock in Novo Nordisk. MHO has received payments or honoraria for lectures, presentations or educational events from AstraZeneca and Boehringer Ingelheim, has an unpaid position as chair of the Danish Hypertension Society, and is a nucleus member of the Working Group for Prevention and Rehabilitation, Danish Society of Cardiology. None of these studies have any relation to the present study. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.

: AV conceived and designed the study. JSN was the principal manager of the Danish Center for Strategic Research in Type 2 Diabetes (DD2). ALH performed the statistical analysis, prepared the first draft of the manuscript, and revised the draft. All authors contributed to the interpretation of data and critically revised the content of the draft. AV and RWT supervised the study. All authors gave final approval of the version to be published. As such, they had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. AV is the guarantor of the study.